• Q32 Bio flagged new 36-week results from its Phase 2a SIGNAL-AA Part B trial of bempikibart in severe alopecia areata.
• Data will be presented at the EADV Congress in Vienna on Sept. 30, 2026, including early findings from a 16-week off-drug period.
• Trial readout indicates hair regrowth that persisted after treatment stopped, supporting bempikibart’s potential as a differentiated immune-targeting therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Q32 Bio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE52557) on September 21, 2026, and is solely responsible for the information contained therein.